DiaMonTech submits to FDA pre-submission application for non-invasive blood glucose meter D-Base
Berlin, 9 September 2020
With the submission of the pre-submissionapplication to the US Food and Drug Administration (FDA), the company has initiated the approval process of its product D-Base as a medical device in the US.
D-Base uses the innovative DiaMonTech technology for non-invasive, precise,and painless measurement of blood glucose levels and it is optimized for use in professional environments such as diabetes centers.
For diabetes patients and prediabetics, DiaMonTech is developing the smaller D-Pocket, which builds on the same laser technology.
In the next step of the approval process, DiaMonTech will align with the FDA on the regulatory approval path for the US.
